{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunoglobulin+G&page=5", "query": { "intervention": "Immunoglobulin G", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 882, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunoglobulin+G&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunoglobulin+G&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T21:52:58.087Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03441048", "title": "Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Lintuzumab-Ac-225", "type": "BIOLOGICAL" }, { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2018-05-22", "completion_date": "2024-05-22", "has_results": false, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 1, "location_summary": "Milwuakee, Wisconsin", "locations": [ { "city": "Milwuakee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03441048" }, { "nct_id": "NCT03693300", "title": "A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 117, "start_date": "2019-04-16", "completion_date": "2023-04-21", "has_results": true, "last_update_posted_date": "2024-06-18", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 2, "location_summary": "Gainesville, Georgia • Knoxville, Tennessee", "locations": [ { "city": "Gainesville", "state": "Georgia" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03693300" }, { "nct_id": "NCT01552434", "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Castleman Disease", "Digestive System Carcinoma", "Erdheim-Chester Disease", "Lip and Oral Cavity Carcinoma", "Lymphangioleiomyomatosis", "Malignant Endocrine Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Male Reproductive System Neoplasm", "Malignant Neoplasm", "Malignant Respiratory Tract Neoplasm", "Malignant Thoracic Neoplasm", "Malignant Urinary System Neoplasm", "Mesothelial Neoplasm", "Metastatic Malignant Neoplasm", "Metastatic Urothelial Carcinoma", "Neurofibromatosis Type 2", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Breast Carcinoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Digestive System Carcinoma", "Recurrent Female Reproductive System Carcinoma", "Recurrent Male Reproductive System Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Pharyngeal Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Malignant Neoplasm", "Soft Tissue Neoplasm", "Stage III Breast Cancer AJCC v7", "Stage III Pharyngeal Cancer", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Pharyngeal Cancer", "Stage IVA Pharyngeal Cancer", "Stage IVB Pharyngeal Cancer", "Stage IVC Pharyngeal Cancer", "Thyroid Gland Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 154, "start_date": "2012-10-16", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552434" }, { "nct_id": "NCT03630211", "title": "Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis", "Diffuse Sclerosis Systemic", "Interstitial Lung Disease", "Pulmonary Hypertension" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "Intravenous immunoglobulin", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Anti Thymocyte Globulin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Paul Szabolcs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "8 Years to 60 Years" }, "enrollment_count": 8, "start_date": "2018-07-31", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630211" }, { "nct_id": "NCT02464657", "title": "Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Acute Myeloid Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Solu-medrol", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2015-07", "completion_date": "2020-05-07", "has_results": true, "last_update_posted_date": "2021-10-07", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02464657" }, { "nct_id": "NCT02042027", "title": "Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Corneal Neovascularization", "Corneal Graft Failure", "Anterior Segment Inflammation" ], "interventions": [ { "name": "Gamunex-C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-07", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-08-05", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02042027" }, { "nct_id": "NCT03801369", "title": "AMTEC IIT: Phase 2 Multiarm Study in TNBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Gordon Mills, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-12-12", "completion_date": "2024-12-23", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03801369" }, { "nct_id": "NCT02873195", "title": "Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Recurrent Colorectal Carcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-07-07", "completion_date": "2023-12-01", "has_results": true, "last_update_posted_date": "2024-08-23", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02873195" }, { "nct_id": "NCT04607954", "title": "Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Resistant Lung Small Cell Carcinoma", "Platinum-Sensitive Lung Small Cell Carcinoma", "Recurrent Extensive Stage Lung Small Cell Carcinoma", "Refractory Extensive Stage Lung Small Cell Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2020-12-04", "completion_date": "2031-05-01", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04607954" }, { "nct_id": "NCT05269082", "title": "A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Drug Hypersensitivity" ], "interventions": [ { "name": "No intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 72, "start_date": "2022-04-05", "completion_date": "2022-09-19", "has_results": false, "last_update_posted_date": "2022-09-23", "last_synced_at": "2026-10-08T21:52:58.087Z", "location_count": 1, "location_summary": "Wilmington, North Carolina", "locations": [ { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05269082" } ] }